Cargando…

Oligomeric Forms of Human Amyloid-Beta(1–42) Inhibit Antigen Presentation

Genetic, clinical, biochemical and histochemical data indicate a crucial involvement of inflammation in Alzheimer's disease (AD), but harnessing the immune system to cure or prevent AD has so far proven difficult. Clarifying the cellular heterogeneity and signaling pathways associated with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gericke, Christoph, Mallone, Anna, Engelhardt, Britta, Nitsch, Roger M., Ferretti, Maria Teresa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290131/ https://www.ncbi.nlm.nih.gov/pubmed/32582162 http://dx.doi.org/10.3389/fimmu.2020.01029

Ejemplares similares

Effects of α-Lipoic Acid on Phagocytosis of Oligomeric Beta-Amyloid(1–42) in BV-2 Mouse Microglial Cells
por: Ko, Chih-Yuan, et al.
Publicado: (2022)

Making Insulin and Staying Out of Autoimmune Trouble: The Beta-Cell Conundrum
por: Carré, Alexia, et al.
Publicado: (2021)

Reduced β-amyloid pathology in an APP transgenic mouse model of Alzheimer’s disease lacking functional B and T cells
por: Späni, Claudia, et al.
Publicado: (2015)

Polymorphic SERPINA3 prolongs oligomeric state of amyloid beta
por: Akbor, Maruf Mohammad, et al.
Publicado: (2021)

Amyloid β Oligomeric Species Present in the Lag Phase of Amyloid Formation
por: Wolff, Martin, et al.
Publicado: (2015)

Comparison of the amyloid pore forming properties of rat and human Alzheimer’s beta-amyloid peptide 1-42: Calcium imaging data
por: Di Scala, Coralie, et al.
Publicado: (2016)

Tyramine and Amyloid Beta 42: A Toxic Synergy
por: Dhakal, Sudip, et al.
Publicado: (2020)

AFM Probing of Amyloid-Beta 42 Dimers and Trimers
por: Maity, Sibaprasad, et al.
Publicado: (2020)

α-Synuclein Aggregation Is Triggered by Oligomeric Amyloid-β 42 via Heterogeneous Primary Nucleation
por: Vadukul, Devkee M., et al.
Publicado: (2023)

Acyl peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide
por: Yamin, Rina, et al.
Publicado: (2009)

Differential regulation of insulin signalling by monomeric and oligomeric amyloid beta-peptide
por: Molina-Fernández, Rubén, et al.
Publicado: (2022)

Dynamic changes of oligomeric amyloid β levels in plasma induced by spiked synthetic Aβ(42)
por: An, Seong Soo A., et al.
Publicado: (2017)

Elevated Plasma Oligomeric Amyloid β-42 Is Associated with Cognitive Impairments in Cerebral Small Vessel Disease
por: Qu, Wensheng, et al.
Publicado: (2023)

Amyloid-beta 42 adsorption following serial tube transfer
por: Toombs, Jamie, et al.
Publicado: (2014)

Amyloid-Beta (Aβ) D7H Mutation Increases Oligomeric Aβ42 and Alters Properties of Aβ-Zinc/Copper Assemblies
por: Chen, Wei-Ting, et al.
Publicado: (2012)

Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2018)

The Role of Age on Beta-Amyloid(1–42) Plasma Levels in Healthy Subjects
por: Zecca, Chiara, et al.
Publicado: (2021)

Interaction of the Molecular Chaperone DNAJB6 with Growing Amyloid-beta 42 (Aβ42) Aggregates Leads to Sub-stoichiometric Inhibition of Amyloid Formation
por: Månsson, Cecilia, et al.
Publicado: (2014)

Plasma amyloid beta 42 is a biomarker for patients with hereditary, but not sporadic, cerebral amyloid angiopathy
por: de Kort, Anna M., et al.
Publicado: (2023)

Mitochondrial Disruption by Amyloid Beta 42 Identified by Proteomics and Pathway Mapping
por: Sinclair, Patricia, et al.
Publicado: (2021)

The Relationship between Different Assays for Detection and Quantification of Amyloid Beta 42 in Human Cerebrospinal Fluid
por: Ellis, Teresa A., et al.
Publicado: (2012)

Erratum: Plasma Oligomeric Beta Amyloid in Alzheimer's Disease with History of Agent Orange Exposure
por: Yang, YoungSoon, et al.
Publicado: (2023)

The calcium-free form of atorvastatin inhibits amyloid-β(1–42) aggregation in vitro
por: Nedaei, Hadi, et al.
Publicado: (2022)

Brain Cells Release Calreticulin That Attracts and Activates Microglia, and Inhibits Amyloid Beta Aggregation and Neurotoxicity
por: Reid, Kyle M., et al.
Publicado: (2022)

LRPAP1 is released from activated microglia and inhibits microglial phagocytosis and amyloid beta aggregation
por: Reid, Kyle M., et al.
Publicado: (2023)

The Length of N-Glycans of Recombinant H5N1 Hemagglutinin Influences the Oligomerization and Immunogenicity of Vaccine Antigen
por: Macioła, Agnieszka Katarzyna, et al.
Publicado: (2017)

Decoding the Roles of Amyloid-β (1–42)’s Key Oligomerization Domains toward Designing Epitope-Specific Aggregation Inhibitors
por: Im, Dongjoon, et al.
Publicado: (2023)

Structural Reorganisation and Potential Toxicity of Oligomeric Species Formed during the Assembly of Amyloid Fibrils
por: Cheon, Mookyung, et al.
Publicado: (2007)

Amyloid-Beta 1-42 Cross-Reactive Antibody Prevalent in Human Sera May Contribute to Intraneuronal Deposition of A-Beta-P-42
por: Vojdani, Aristo, et al.
Publicado: (2018)

Antigen-Presenting Cells and Antigen Presentation in Tertiary Lymphoid Organs
por: Hughes, Catherine E., et al.
Publicado: (2016)

Nasal mucosal inhalation of amyloid-beta peptide 3–10 defective adenovirus attenuates cytotoxicity induced by beta-amyloid (1–42)
por: Jiang, Tongzi, et al.
Publicado: (2014)

CSF beta-amyloid 1–42 – what are we measuring in Alzheimer's disease?
por: Hu, William T, et al.
Publicado: (2015)

The HSP40 chaperone Ydj1 drives amyloid beta 42 toxicity
por: Ring, Julia, et al.
Publicado: (2022)

Serum Amyloid Beta42 Is Not Eliminated by the Cirrhotic Liver: A Pilot Study
por: Wiest, Reiner, et al.
Publicado: (2021)

Neurotoxic amyloid beta oligomeric assemblies recreated in microfluidic platform with interstitial level of slow flow
por: Choi, Yoon Jung, et al.
Publicado: (2013)

On the Role of Platelet-Generated Amyloid Beta Peptides in Certain Amyloidosis Health Complications
por: Inyushin, Mikhail, et al.
Publicado: (2020)

Emergence of Alternative Structures in Amyloid Beta 1-42 Monomeric Landscape by N-terminal Hexapeptide Amyloid Inhibitors
por: Chakraborty, Srirupa, et al.
Publicado: (2017)

Antigen Presentation in the Lung
por: Kawasaki, Takumi, et al.
Publicado: (2022)

Chronic Intranasal Treatment with an Anti-Aβ(30-42) scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease
por: Cattepoel, Susann, et al.
Publicado: (2011)

Endocytic pathways mediating oligomeric Aβ42 neurotoxicity
por: Yu, Chunjiang, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_vjr6bm6mi0ih9kfsn2us4c0svi